R^{1a} and R^{2a} are each independently hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted 3-6 membered heterocycloalkyl, or optionally substituted C_{1-6} haloalkyl;

Y is -N- or -CH-;

X^1 is $-CR^{1b}-$ or -N-;

X^2 is $-CR^{2b}-$ or -N-;


X^3 is $-CR^{3b}-$ or -N-;

X^4 is $-CR^{4b}-$ or -N-;

X^5 is $-CR^{5b}-$ or -N-;

X^6 is $-CR^{6b}-$ or -N-;

R^{1b}-R^{6b} are each independently hydrogen, halogen, hydroxyl, C_{1-4} alkoxy optionally substituted with one or more halo substituents, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, nitro, $-NR^{1c}R^{2c}$, $-NHC(O)R^{3c}$, or $-C(O)NR^{4c}R^{5c}$;

L is a bond, -O-, -C(O)-, $-NR^{6c}-$, or $-OCHR^{7c}-*$, wherein * represents the point of attachment to 


;

R^{1c}-R^{7c} are each independently hydrogen or C_{1-3} alkyl;

a^1, a^2, b^1, and c^4 are each independently 0, 1, 2, or 3; and

b^2, c^1-c^3, d^1-d^4, e^1, and e^2 are each independently 1, 2, or 3.

[0005b] In another aspect of the present disclosure, there is provided a compound of Formula (I-1):



(I-1),

or a pharmaceutically acceptable salt thereof, wherein:

L is a bond, -O-, -C(O)-, or -NR^{6c}-;

R^{1c}-R^{6c} are each independently hydrogen or C_{1-3} alkyl;

a^1, a^2, and b^1 are each independently 0, 1, 2, or 3; and


b^2, c^1-c^4, d^1-d^4, e^1, and e^2 are each independently 1, 2, or 3.

[0005d] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

[0005e] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer, a bacterial and/or viral infection, insulin resistance, type II diabetes, chondrocalcinosis, osteoarthritis, soft-tissue calcification disorder, calcium pyrophosphate deposition disorder, or hypophosphatasia.

[0005f] In a further aspect of the present disclosure, there is provided a compound disclosed herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0006] The present disclosure provides compounds of Formula (I), compositions thereof, and methods of using said compounds and compositions thereof for the treatment of diseases or conditions associated with ENPP1. In one example, provided is a compound of Formula (I)



(I),